Translational Research for Ion Beam Therapy
Dr. Jose Alberto Vedelago
Research Group Leader
Proton and light ion beam therapy is an advanced cancer treatment modality. By improving the potential risk quantification associated with this treatment modality, we intend to increase the number of patients who can benefit from it.
Introduction
Our research group mainly focuses on assessing the secondary radiation during proton and light ion beam therapy for cancer treatment. This is particularly relevant for pediatric and pregnant patients since the associated risks of secondary cancer are more relevant compared to other patients (Vedelago et al 2024). Our primary research partner is the Heidelberg Ion Beam Therapy Center (HIT) at the Heidelberg University Hospital (UKHD), and our main funding institutions are the German Research Foundation (DFG) as well as the Wilhelm Sander Stiftung.
The research activities we work on span from Monte Carlo simulations for characterizing secondary neutron production during ion beam therapy (Vedelago et al 2022a; Geser et al 2024; Stengl et al 2025a) to the advancement of neutron dosimetry techniques by using Fluorescent Nuclear Track Detectors (FNTDs), with a focus on high-energy neutrons (Becker et al 2022; Schmidt et al 2024; Schmidt et al 2025a) and in-phantom out-of-field doses (Schmidt et al 2026). One of the latest studies in collaboration with the Eurados European Radiation Dosimetry Group (EURADOS) was dedicated to comparing out-of-field neutron doses (Bolzonella et al 2025) and measurements of the secondary neutrons' energy distribution (Stengl et al 2026). Additionally, we have reviewed the update of the International Code of Practice (TRS-398) of the International Atomic Energy Agency (IAEA) for reference dosimetry (Vedelago et al 2022b).
We also have many projects in collaboration with other groups from our department. For instance, the dosimetry for carbon ion radiotherapy in the advanced anthropomorphic phantoms developed by the Medical Engineering Group E0405 (Stengl et al 2023; Stengl et al 2025b), and a joint project for gel dosimetry of carbon ions with the Applied Medical Radiation Physics Group E0402 (Bayer et al 2024). As new projects, we are starting a pilot study about using Machine Learning for neutron dosimetry with FNTDs with the Computational Patient Models Group E0401, and we intend to integrate out-of-field dose models into MatRad in collaboration with the Radiotherapy Optimization Group E0404. Furthermore, in collaboration with the Division of Biomedical Physics in Radiation Oncology, we performed the dosimetry of carbon ion mini-beams (Stengl et al 2024).